Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Extends Review Of Wyeth/Progenics Methylnaltrexone NDA Until April

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has pushed back the action date on Wyeth and Progenics' NDA for the subcutaneous formulation of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, until April 30, the companies announced Jan. 10

You may also be interested in...


Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief

As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts